77 related articles for article (PubMed ID: 1492636)
21. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
22. [Predictive value of the serum PSA level in patients having undergone neo-adjuvant hormone treatment before radical prostatectomy].
Wildschutz T; Janssen T; Schulman C
Acta Urol Belg; 1995 Mar; 63(1):79-82. PubMed ID: 7537012
[TBL] [Abstract][Full Text] [Related]
23. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
24. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
25. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy for clinical T4 prostate cancer.
Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
[TBL] [Abstract][Full Text] [Related]
27. [The treatment of locally advanced (T3) prostatic carcinoma using radical prostatectomy or radiotherapy. A review].
van den Ouden D; Schröder FH
Tijdschr Gerontol Geriatr; 1998 Apr; 29(2):74-9. PubMed ID: 9615377
[TBL] [Abstract][Full Text] [Related]
28. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
29. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
[TBL] [Abstract][Full Text] [Related]
30. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
31. Perioperative morbidity of laparoscopic radical prostatectomy compared with open radical retropubic prostatectomy.
Brown JA; Garlitz C; Gomella LG; McGinnis DE; Diamond SM; Strup SE
Urol Oncol; 2004; 22(2):102-6. PubMed ID: 15082005
[TBL] [Abstract][Full Text] [Related]
32. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
Wieder JA; Soloway MS
J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant hormonal treatment before radical prostatectomy.
Watson RB; Soloway MS
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):48-55; discussion 55-6. PubMed ID: 8725891
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
[TBL] [Abstract][Full Text] [Related]
35. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project.
Schmidt JD; Gibbons RP; Murphy GP; Bartolucci A
Prostate; 1996 Jan; 28(1):51-7. PubMed ID: 8545281
[TBL] [Abstract][Full Text] [Related]
37. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
38. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment.
Hugosson J; Abrahamsson PA; Ahlgren G; Aus G; Lundberg S; Schelin S; Schain M; Pedersen K
Eur Urol; 1996; 29(4):413-9. PubMed ID: 8791047
[TBL] [Abstract][Full Text] [Related]
39. [Comments on radical prostatectomy three month after hormone therapy].
Selvaggi FP; Battaglia M; Martino P; Disabato G; Traficante A; Bufo P
Minerva Urol Nefrol; 1995 Dec; 47(4):215-7. PubMed ID: 8711595
[No Abstract] [Full Text] [Related]
40. Hepatocellular carcinoma during hormonotherapy for prostatic cancer.
Kattan J; Spatz A; Culine S; Terrier-Lacombe MJ; Elias D; Droz JP
Am J Clin Oncol; 1994 Oct; 17(5):390-2. PubMed ID: 8092108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
